title: Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.
abstract: A population pharmacokinetic model of doripenem was constructed using data pooled from phase 1, 2, and 3 studies utilizing nonlinear mixed effects modeling. A 2-compartment model with zero-order input and first-order elimination best described the log-transformed concentration-versus-time profile of doripenem. The model was parameterized in terms of total clearance (CL), central volume of distribution (V(c)), peripheral volume of distribution (V(p)), and distribution clearance between the central and peripheral compartments (Q). The final model was described by the following equations (for jth subject): CL(j) (liters/h) = 13.6.(CL(CR)(j)/98 ml/min)(0.659).(1 + CL(race)(j) [0 for Caucasian]); V(c)(j) (liters) = 11.6.(weight(j)/73 kg)(0.596); Q(j) (liters/h) = 4.74.(weight(j)/73)(1.06); and V(p)(j) (liters) = 6.04.(CL(CR)(j)/98 ml/min)(0.417).(weight(j)/73 kg)(0.840).(age(j)/40 years)(0.307). According to the final model, population mean parameter estimates and interindividual variability (percent coefficient of variation [% CV]) for CL (liters/h), V(c) (liters), V(p) (liters), and Q (liters/h) were 13.6 (19%), 11.6 (19%), 6.0 (25%), and 4.7 (42%), respectively. Residual variability, estimated using three separate additive residual error models, was 0.17 standard deviation (SD), 0.55 SD, and 0.92 SD for phase 1, 2, and 3 data, respectively. Creatinine clearance was the most significant predictor of doripenem clearance. Mean Bayesian clearance was approximately 33%, 55%, and 76% lower for individuals with mild, moderate, or severe renal impairment, respectively, than for those with normal renal function. The population pharmacokinetic model based on healthy volunteer data and patient data informs us of doripenem disposition in a more general population as well as of the important measurable intrinsic and extrinsic factors that significantly influence interindividual pharmacokinetic differences.
authors.affiliation: Clinical Pharmacology, Advanced PK/PD Modeling and Simulation, Johnson & Johnson Pharmaceutical Research & Development, LLC, Titusville, NJ 08560, USA. PNandy@its.jnj.com
authors.forename: Partha
authors.initials: P
authors.lastname: Nandy
authors.forename: Mahesh N
authors.initials: MN
authors.lastname: Samtani
authors.forename: Rachel
authors.initials: R
authors.lastname: Lin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D001424:Bacterial Infections / Q000188:drug therapy / Q000378:metabolism; D001499:Bayes Theorem; D015780:Carbapenems / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D003404:Creatinine / Q000378:metabolism; D016638:Critical Illness; D003428:Cross Infection / Q000188:drug therapy / Q000378:metabolism; D000077726:Doripenem; D005260:Female; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D008954:Models, Biological; D017711:Nonlinear Dynamics; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000378:metabolism; D011704:Pyelonephritis / Q000188:drug therapy / Q000378:metabolism; D051437:Renal Insufficiency / Q000378:metabolism; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000378:metabolism; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D003404:Creatinine; D000077726:Doripenem
references.citation: J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):171-92
references.pmid: 11381569
references.citation: J Pharmacokinet Biopharm. 1977 Oct;5(5):445-79
references.pmid: 925881
references.citation: J Pharmacokinet Biopharm. 1994 Oct;22(5):431-45
references.pmid: 7791040
references.citation: Clin Pharmacokinet. 2000 Sep;39(3):185-201
references.pmid: 11020134
references.citation: Drugs. 2008;68(14):2021-57
references.pmid: 18778123
references.citation: Agents Actions. 1977 Sep;7(3):379-82
references.pmid: 596321
references.citation: Nephron. 1976;16(1):31-41
references.pmid: 1244564
references.citation: Clin Microbiol Infect. 2005 Dec;11(12):974-84
references.pmid: 16307551
references.citation: Antimicrob Agents Chemother. 2008 Dec;52(12):4388-99
references.pmid: 18779357
references.citation: Fundam Clin Pharmacol. 2003 Dec;17(6):645-50
references.pmid: 15015709
references.citation: J Antimicrob Chemother. 1995 Jul;36 Suppl A:63-71
references.pmid: 8543500
references.citation: J Clin Pharmacol. 2009 Jul;49(7):798-806
references.pmid: 19553404
references.citation: J Pharmacokinet Biopharm. 1992 Oct;20(5):511-28
references.pmid: 1287200
references.citation: Diagn Microbiol Infect Dis. 2005 May;52(1):71-4
references.pmid: 15878447
references.citation: Clin Infect Dis. 1997 Feb;24 Suppl 2:S249-55
references.pmid: 9126700
references.citation: J Clin Pharmacol. 2006 Oct;46(10):1171-8
references.pmid: 16988206
references.citation: Drugs. 2007;67(7):1027-52
references.pmid: 17488146
references.citation: Antimicrob Agents Chemother. 2008 Oct;52(10):3478-83
references.pmid: 18644951
references.citation: Antimicrob Agents Chemother. 2005 Sep;49(9):3944-7
references.pmid: 16127078
references.citation: Diagn Microbiol Infect Dis. 2009 Apr;63(4):409-14
references.pmid: 19249182
references.citation: Gut. 1977 Dec;18(12):1054-8
references.pmid: 606633